Gilead Sciences’s Arcellx ACLX Stock Holding History

Gilead Sciences’s Portfolio ACLX Stock Details ACLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-6,720,803	Closed	-$772M	–	6
2026 Q1	$772M	Hold	6,720,803	–	–	36.44%	1
2025 Q4	$438M	Hold	6,720,803	–	–	22.64%	3
2025 Q3	$552M	Hold	6,720,803	–	–	30.8%	2
2025 Q2	$443M	Hold	6,720,803	–	–	34.57%	2
2025 Q1	$441M	Hold	6,720,803	–	–	37.32%	1
2024 Q4	$515M	Buy	+6,720,803	New	+$581M	33.23%	1

Other funds holding ACLX

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Gilead Sciences's ACLX Position: Q2 2026 in Review

Gilead Sciences sold out of Arcellx (ACLX) in Q2 2026, closing a stake of 6,720,803 shares — an estimated $772M sold.

Gilead Sciences first reported a position in ACLX in Q4 2024 and held it in 6 quarters. The position peaked at $772M in Q1 2026. 2 funds tracked by Wall St. Rank hold ACLX as of Q2 2026.

Gilead Sciences reported no remaining Arcellx position as of Q2 2026 after selling out during the quarter.
Gilead Sciences sold 6,720,803 Arcellx shares in Q2 2026, an estimated $772M.
Gilead Sciences first reported a position in Arcellx in Q4 2024 and held it in 6 quarters.
Gilead Sciences's Arcellx position peaked at $772M in Q1 2026.
2 funds tracked by Wall St. Rank held Arcellx as of Q2 2026.

Based on Gilead Sciences's 13F filing for Q2 2026, filed 3 Aug 2026.